This event has passed. You can read highlights from the interview and watch the YouTube recording of the talk here.
On Wednesday, June 21st, 2:00 p.m. PT/5:00 p.m. ET, pioneering genetic medicine expert and physician Ronald G. Crystal of Cornell University’s Weill Medical College joins Being Patient’s editor in chief Deborah Kan for a discussion on gene therapy in relation to Alzheimer’s disease.
As a pioneer in the field of genetic medicine, he started working in gene therapy in the late 1980s. His work has helped to form the basis for all subsequent work in adenovirus-based gene therapies and vaccines. Crystal has carried out human trials of gene therapy for diseases including cystic fibrosis, cardiac ischemia, cancer and central nervous system disorders, and most recently, he has been working on gene therapies for Alzheimer’s disease: For example, his laboratory developed a gene therapy designed to reduce the high risk of Alzheimer’s associated with the APOE4 genetic variant — aka the “Alzheimer’s gene” — a strategy that is currently in clinical trials.
Crystal is the director of the Belfer Gene Therapy Core Facility and attending physician at the New York-Presbyterian Hospital/Weill Cornell Medical Center, and he chairs the Cornell University Weill Medical College genetic medicine department. He’s also responsible for a number of biomedical patents, and he’s founded multiple gene therapy-focused biotech companies including Lexeo Therapeutics, a New York City-based clinical-stage gene therapy company focused on addressing genetically defined cardiovascular and central nervous system diseases.
In this Live Talk, he’ll share his expert take on the past, present future of the field with regard to neurodegenerative diseases like Alzheimer’s. This Live Talk is sponsored by Lexeo Therapeutics.